Overview

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.
Phase:
Phase 1
Details
Lead Sponsor:
Megan Nicklay
Treatments:
Bupivacaine